GMED
Globus Medical Inc
$
58.650
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
58.900
Open
56.000
VWAP
58.24
Vol
3.66M
Mkt Cap
7.92B
Low
55.250
Amount
213.45M
EV/EBITDA(TTM)
8.74
Total Shares
135.06M
EV
6.86B
EV/OCF(TTM)
10.37
P/S(TTM)
1.89
Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions with a focus on improving the quality of life of patients with musculoskeletal disorders. The Company offers a portfolio of differentiated technologies that are used to treat a variety of musculoskeletal conditions. Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and surgical instruments used in a range of spinal, orthopedic and neurosurgical procedures. Its spine products address the conditions affecting the spine, including degenerative conditions, deformities, tumors, and trauma. It provides solutions that facilitate both open and minimally invasive surgery techniques. It includes traditional fusion implants, such as pedicle screws and rod systems, and others. Its orthopedic trauma solutions are designed to treat a variety of orthopedic fracture patterns and patient anatomies in the upper and lower extremities, as well as the hip.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
702.74M
+17.49%
0.803
+18.14%
778.55M
+18.45%
0.907
+7.98%
734.27M
+17.35%
0.788
-5.11%
Estimates Revision
The market is revising Upward the revenue expectations for Globus Medical, Inc. (GMED) for FY2025, with the revenue forecasts being adjusted by 3.87% over the past three months. During the same period, the stock price has changed by 5.07%.
Revenue Estimates for FY2025
Revise Upward
+3.87%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-6.55%
In Past 3 Month
Stock Price
Go Up
+5.07%
In Past 3 Month
14 Analyst Rating
41.38% Upside
Wall Street analysts forecast GMED stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GMED is 82.92 USD with a low forecast of 68.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
6 Hold
0 Sell
Moderate Buy
41.38% Upside
Current: 58.650
Low
68.00
Averages
82.92
High
105.00
41.38% Upside
Current: 58.650
Low
68.00
Averages
82.92
High
105.00
Canaccord
Buy
downgrade
$97 -> $90
2025-07-22
Reason
Canaccord
Price Target
$97 -> $90
2025-07-22
downgrade
Buy
Reason
Canaccord lowered the firm's price target on Globus Medical to $90 from $97 and keeps a Buy rating on the shares. The firm updated its model to reflect the Q2/25 preliminary results which showed revenues in the middle of both the firm's and the Streets consensus. The company also reaffirmed FY25 revenue to be in the the range of $2.80B-$2.90B and its guidance for EPS to be in the range $3.00-$3.30.
Jefferies
Buy
downgrade
$90 -> $88
2025-07-21
Reason
Jefferies
Price Target
$90 -> $88
2025-07-21
downgrade
Buy
Reason
Jefferies lowered the firm's price target on Globus Medical to $88 from $90 and keeps a Buy rating on the shares. The firm views the company's pre-announced results as better than feared, given disruption in Q1 and investor concerns about Nevro. Jefferies lowered estimates to above the midpoint from the high end and trimmed its price target, though maintains a Buy view.
Morgan Stanley
Overweight
downgrade
$75 -> $68
2025-07-15
Reason
Morgan Stanley
Price Target
$75 -> $68
2025-07-15
downgrade
Overweight
Reason
Morgan Stanley lowered the firm's price target on Globus Medical to $68 from $75 and keeps an Overweight rating on the shares. The firm continues to like the MedTech industry setup into Q2 on relative stability in procedure volumes and hospital capital expenditures across the space, the analyst tells investors in a research note.
Truist
Hold
downgrade
$80 -> $68
2025-05-12
Reason
Truist
Price Target
$80 -> $68
2025-05-12
downgrade
Hold
Reason
Truist lowered the firm's price target on Globus Medical to $68 from $80 and keeps a Hold rating on the shares. The firm cites the company's surprising Q1 earnings and revenue miss, noting that while distributor and supply chain items should prove somewhat transitory, the weaker capital sales from elongating robot deals is a bit more concerning, the analyst tells investors in a research note.
BTIG
Ryan Zimmerman
Buy
downgrade
$88 -> $77
2025-05-09
Reason
BTIG
Ryan Zimmerman
Price Target
$88 -> $77
2025-05-09
downgrade
Buy
Reason
BTIG analyst Ryan Zimmerman lowered the firm's price target on Globus Medical to $77 from $88 and keeps a Buy rating on the shares. The company's Q1 results fell short of expectations and the top-line shortfall was due to a variety of factors - softer sales of wound care products, slower neuromonitoring reimbursement, supply chain integration dynamics, and longer sales cycles in Enabling Tech, the analyst tells investors in a research note.
Piper Sandler
Matt O'Brien
Overweight
downgrade
$100 -> $80
2025-05-09
Reason
Piper Sandler
Matt O'Brien
Price Target
$100 -> $80
2025-05-09
downgrade
Overweight
Reason
Piper Sandler analyst Matt O'Brien lowered the firm's price target on Globus Medical to $80 from $100 and keeps an Overweight rating on the shares. The firm notes the company reported Q1 results that saw it miss meaningfully on the top-and-bottom lines. There were a number of factors including soft enabling-tech deal closures, and supply chain disruption. Piper understands investor frustration here, especially given the integration appeared to have been going well to this point, but the firm believes many of these headwinds are transient and it has seen this organization recover from other bumps in the past.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Globus Medical Inc (GMED.N) is 17.77, compared to its 5-year average forward P/E of 27.16. For a more detailed relative valuation and DCF analysis to assess Globus Medical Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Undervalued
5Y Average PE
27.16
Current PE
17.77
Overvalued PE
33.50
Undervalued PE
20.82
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
13.86
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
17.58
Undervalued EV/EBITDA
10.14
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
5.09
Current PS
0.00
Overvalued PS
6.88
Undervalued PS
3.31
Financials
Annual
Quarterly
FY2025Q2
YoY :
+18.37%
745.34M
Total Revenue
FY2025Q2
YoY :
+9.56%
129.17M
Operating Profit
FY2025Q2
YoY :
+538.68%
202.85M
Net Income after Tax
FY2025Q2
YoY :
+547.83%
1.49
EPS - Diluted
FY2025Q2
YoY :
+18.30%
31.30M
Free Cash Flow
FY2025Q2
YoY :
+1.39%
63.38
Gross Profit Margin - %
FY2025Q2
YoY :
+176.25%
19.89
FCF Margin - %
FY2025Q2
YoY :
+440.08%
27.22
Net Margin - %
FY2025Q2
YoY :
+504.41%
8.22
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
1.8M
USD
2
0-12
Months
22.2M
USD
11
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
469.1K
Volume
6
6-9
Months
2.4M
Volume
7
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
4
444.3K
Volume
Months
6-9
6
2.4M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
8.0K
USD
1
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
1.8M
USD
2
0-12
Months
22.2M
USD
11
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
GMED News & Events
Events Timeline
2025-08-07 (ET)
2025-08-07
16:27:46
Globus Medical sees FY25 non-GAAP EPS $3.00-$3.30, consensus $3.16
2025-08-07
16:26:14
Globus Medical reports Q2 non-GAAP EPS 86c, consensus 75c
2025-07-21 (ET)
2025-07-21
11:42:53
Roth bullish on Globus Medical amid CEO Transition, solid pre-reported results
Sign Up For More Events
Sign Up For More Events
News
9.5
08-08NASDAQ.COMPinnedGlobus Medical (GMED) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
9.5
08-07NASDAQ.COMPinnedGlobus Medical (GMED) Q2 Revenue Up 18%
3.0
08-06Yahoo FinanceGlobus Medical (GMED) Q2 Earnings: What To Expect
Sign Up For More News
People Also Watch
COKE
Coca-Cola Consolidated Inc
114.110
USD
-0.11%
FUTU
Futu Holdings Ltd
160.920
USD
+2.77%
MTZ
MasTec Inc
181.300
USD
-0.92%
CHRW
CH Robinson Worldwide Inc
116.780
USD
-0.88%
WPC
WP Carey Inc
65.880
USD
+0.15%
CAG
Conagra Brands Inc
19.250
USD
0.00%
NDSN
Nordson Corp
211.040
USD
-0.48%
KMX
Carmax Inc
54.960
USD
-0.52%
ITT
ITT Inc
165.670
USD
+0.40%
UHS
Universal Health Services Inc
172.300
USD
+1.94%
FAQ
What is Globus Medical Inc (GMED) stock price today?
The current price of GMED is 58.65 USD — it has increased 8.47 % in the last trading day.
What is Globus Medical Inc (GMED)'s business?
What is the price predicton of GMED Stock?
What is Globus Medical Inc (GMED)'s revenue for the last quarter?
What is Globus Medical Inc (GMED)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Globus Medical Inc (GMED)'s fundamentals?
How many employees does Globus Medical Inc (GMED). have?